MPM BioImpact’s Viracta Therapeutics VIRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
– Sell
-80,283
Closed -$1.17M – 13
2020
Q1
$1.17M Hold
80,283
– – 0.71% 9
2019
Q4
$949K Buy
+80,283
New +$1.34M 0.34% 11

Other funds holding VIRX

MPM BioImpact's VIRX Position: Q2 2020 in Review

MPM BioImpact sold out of Viracta Therapeutics (VIRX) in Q2 2020, closing a stake of 80,283 shares — an estimated $1.17M sold.

MPM BioImpact first reported a position in VIRX in Q4 2019 and held it in 2 quarters. The position peaked at $1.17M in Q1 2020. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.

  • MPM BioImpact reported no remaining Viracta Therapeutics position as of Q2 2020 after selling out during the quarter.
  • MPM BioImpact sold 80,283 Viracta Therapeutics shares in Q2 2020, an estimated $1.17M.
  • MPM BioImpact first reported a position in Viracta Therapeutics in Q4 2019 and held it in 2 quarters.
  • MPM BioImpact's Viracta Therapeutics position peaked at $1.17M in Q1 2020.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics as of Q2 2020.

Based on MPM BioImpact's 13F filing for Q2 2020, filed 12 Aug 2020.